Literature DB >> 29432982

Deep phenotyping of patients with Tuberous Sclerosis Complex and no mutation identified in TSC1 and TSC2.

Angela Peron1, Aglaia Vignoli2, Francesca La Briola3, Emanuela Morenghi4, Lucia Tansini3, Rosa Maria Alfano5, Gaetano Bulfamante6, Silvia Terraneo7, Filippo Ghelma8, Giuseppe Banderali9, David H Viskochil10, John C Carey10, Maria Paola Canevini2.   

Abstract

Tuberous Sclerosis Complex (TSC) is a multisystemic condition caused by mutations in TSC1 or TSC2, but a pathogenic variant is not identified in up to 10% of the patients. The aim of this study was to delineate the phenotype of pediatric and adult patients with a definite clinical diagnosis of TSC and no mutation identified in TSC1 or TSC2. We collected molecular and clinical data of 240 patients with TSC, assessing over 50 variables. We compared the phenotype of the homogeneous group of individuals with No Mutation Identified (NMI) with that of TSC patients with a TSC1 and TSC2 pathogenic variant. 9.17% of individuals were classified as NMI. They were diagnosed at an older age (p = 0.001), had more frequent normal cognition (p < 0.001) and less frequent epilepsy (p = 0.010), subependymal nodules (p = 0.022) and giant cell astrocytomas (p = 0.008) than patients with TSC2 pathogenic variants. NMI individuals showed more frequent bilateral and larger renal angiomyolipomas (p = 0.001; p = 0.003) and pulmonary involvement (trend) than patients with TSC1 pathogenic variants. Only one NMI individual had intellectual disability. None presented with a subependymal giant cell astrocytoma. Other medical problems not typical of TSC were found in 42.86%, without a recurrent pattern of abnormalities. Other TSC-associated neuropsychiatric disorders and drug-resistance in epilepsy were equally frequent in the three groups. This study provides a systematic clinical characterization of patients with TSC and facilitates the delineation of a distinctive phenotype indicative of NMI patients, with important implications for surveillance.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Deep phenotyping; Genotype-phenotype correlation; No mutation identified (NMI); TSC1; TSC2; Tuberous sclerosis complex (TSC)

Mesh:

Substances:

Year:  2018        PMID: 29432982     DOI: 10.1016/j.ejmg.2018.02.005

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  5 in total

1.  [Genetic analysis of a mosaic case with low proportion mutation of TSC2 gene].

Authors:  Xiaoxiao Jin; Pengzhen Jin; Kai Yan; Yeqing Qian; Minyue Dong
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

2.  Analysis of renal lesions in Chinese tuberous sclerosis complex patients with different types of TSC gene mutations.

Authors:  Wenda Wang; Yang Zhao; Xu Wang; Zhan Wang; Yi Cai; Hanzhong Li; Yushi Zhang
Journal:  Genet Mol Biol       Date:  2022-05-27       Impact factor: 2.087

3.  The Phenotypic Spectrum of Tuberous Sclerosis Complex: A Canadian Cohort.

Authors:  Daad Alsowat; Robyn Whitney; Stacy Hewson; Puneet Jain; Valerie Chan; Nadia Kabir; Kimberly Amburgey; Damien Noone; Mathieu Lemaire; Blathnaid McCoy; Maria Zak
Journal:  Child Neurol Open       Date:  2021-05-04

Review 4.  Healthcare transition from childhood to adulthood in Tuberous Sclerosis Complex.

Authors:  Angela Peron; Maria Paola Canevini; Filippo Ghelma; Fabiano Di Marco; Aglaia Vignoli
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-09-25       Impact factor: 3.908

5.  Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy.

Authors:  Angela Peron; Francesca La Briola; Fabio Bruschi; Silvia Terraneo; Chiara Vannicola; Roberto Previtali; Sabrina Perazzoli; Emanuela Morenghi; Gaetano Bulfamante; Aglaia Vignoli; Maria Paola Canevini
Journal:  Am J Med Genet A       Date:  2020-08-17       Impact factor: 2.578

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.